Companies ›Healthcare ›POAS.K

POAS.K — NYSE Advanced Medical Equipment & Technology

Phaos Technology Holdings (Cayman) Limited

$2,55

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

35,0M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$2,67

Open

$2,58

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Phaos Technology Holdings (Cayman) Limited is a company engaged in the development and provision of advanced medical equipment and technology, primarily serving the healthcare services and equipment sector.

Business. Phaos Technology Holdings (Cayman) Limited (POAS.K) is a healthcare company engaged in the advanced medical equipment and technology industry. The firm operates through a product-sale revenue model, focusing on the development and distribution of medical devices. Headquartered in the Cayman Islands, the company is primarily listed on the New York Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification99 %

SectorHealth Care

Industry groupAdvanced Medical Equipment & Technology

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning POAS.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to POAS.K. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Phaos Technology Holdings (Cayman) Limited (POAS.K) is a healthcare company engaged in the advanced medical equipment and technology industry. The firm operates through a product-sale revenue model, focusing on the development and distribution of medical devices. Headquartered in the Cayman Islands, the company is primarily listed on the New York Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification99 %

SectorHealth Care

Industry groupAdvanced Medical Equipment & Technology

AI synthesis

GENERATED

Phaos Technology Holdings (Cayman) Limited has a market capitalization of SGD 35.23 million, with a market price of SGD 2.57 per share. The company has 13.71 million shares outstanding, with no dilution observed between basic and diluted shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company's profitability and return metrics are not available in the current dataset, and no industry-specific preferred metrics are provided for comparison. As a result, it is not possible to assess Phaos' performance relative to industry medians or to evaluate its return on invested capital (ROIC) or margin performance.

Phaos' revenue concentration and geographic exposure are not disclosed in the available data. The company does not provide segment-level revenue breakdowns or geographic revenue distribution, making it difficult to assess the diversification of its business.

Growth trajectory data is limited. The company's outlook for the current and next fiscal years is not quantified in the dataset, and no numeric deltas are provided to assess revenue or earnings growth expectations.

Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in source documents. Dilution risk is currently low, as there is no difference between basic and diluted shares outstanding. No adjustments have been applied to the valuation metrics, and no dilution sources are disclosed in the available documents.

Recent events, including filings or transcripts, are not available in the dataset. The company's financial and operational disclosures are limited to basic share and valuation data, with no additional commentary or event-driven signals provided.

Key takeaways

Phaos Technology Holdings operates in the advanced medical equipment and technology sector with a market cap of SGD 35.23 million.
The company has no dilution between basic and diluted shares, indicating no immediate dilution risk.
Liquidity risk could not be assessed due to missing balance-sheet data and lack of going-concern language.
Revenue concentration, geographic exposure, and growth trajectory data are not disclosed in the available information.
The company's profitability and return metrics are not available for comparison with industry benchmarks.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation FY

Market price

$2,55

Market cap

$35.2M

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs POAS · multiples and returns

TMO—

Thermo Fisher Scientific Inc

$574,03

214,1B USD

P/E

29,4x

— vs self

Div yield

0,3 %

— vs self

ROE

12,9 %

— vs self

DHR—

Danaher Corp

$197,50

140,1B USD

P/E

38,2x

— vs self

Div yield

—

— vs self

ROE

6,9 %

— vs self

GEHC—

GE HEALTHCARE TECHNOLOGIES INC.

$69,72

31,9B USD

P/E

13,6x

— vs self

Div yield

0,2 %

— vs self

ROE

19,5 %

— vs self

PHG—

PHG

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BSX—

Boston Scientific Corp

$48,54

72,6B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

ISRG—

INTUITIVE SURGICAL, INC.

$376,00

133,2B USD

P/E

287,7x

— vs self

Div yield

—

— vs self

ROE

3,6 %

— vs self

A—

Agilent Technologies Inc

$139,80

39,6B USD

P/E

29,0x

— vs self

Div yield

0,8 %

— vs self

ROE

19,3 %

— vs self

EW—

Edwards Lifesciences Corp

$88,82

51,6B USD

P/E

44,3x

— vs self

Div yield

—

— vs self

ROE

10,4 %

— vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Phaos Technology Holdings (Cayman) Limited Market data — financials · 2026-05-29

Ownership & reference

Insider activity

— missing data

Short positioning

234.5Kshares short-22.7% vs prior

1days to cover

24.5%short of daily vol

6.7Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

POAS.KCanonical

NYSE · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

Net margin (FY 2025-04-30): -3,063.1%Derived (calculated)
Pre-tax income (annual): USD -3.93MSEC XBRL filing
Net income (annual): USD -3.93MSEC XBRL filing
Interest expense (annual): USD 6.48KSEC XBRL filing
Revenue (annual): USD 128.46KSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
Operating cash flow (annual): USD -2.8MSEC XBRL filing
Capex (annual): USD 184KSEC XBRL filing
R&D expense (annual): USD 107.03KSEC XBRL filing
Operating income (annual): USD -4.04MSEC XBRL filing
Cost of revenue (annual): USD 100.07KSEC XBRL filing

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-04-30FILING6-K filing →

2026-04-20FILING6-K filing →

2026-04-13FILING6-K filing →

2026-01-16FILING6-K filing →

2025-11-24FILING6-K filing →

2025-11-14FILING6-K filing →

2025-11-13FILING424B4 filing →

2025-09-18FILING20-F filing →

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread